Genetic Therapy Composition Manufacture TRIZ Cases

Gene editing removes the target antigen and can block TCR signaling, helping CAR-T cells kill malignant T cells without self-destruction.

Microfluidic lipid-coated nanoparticles improve targeted cellular uptake and transfection while reducing liver and spleen accumulation.

Buffer, cryoprotectant, and non-ionic surfactant combinations keep purified AAV particles stable and limit aggregation during storage and freeze-thaw.

Inert stuffer polynucleotides fill AAV packaging capacity to limit residual DNA encapsidation and improve clinical-grade vector purity.

Target-antigen knockout makes CAR-T cells fratricide-resistant, preserving malignant T cell killing while reducing graft versus host risk.

Acid-cleavable PEG lipids and self-assembling peptides stabilize mRNA LNPs in serum, then improve endosome escape and cell uptake.

An RGDLXXL/I capsid motif boosts AAV affinity for αVβ6 to improve muscle transduction after systemic delivery without added off-target uptake.

Inhibiting p53 phosphorylation helps transduced haematopoietic stem cells survive DNA stress and improve engraftment.

Specific AAV6 capsid peptide changes address the gap between T-cell infectivity and efficient HDR-mediated gene editing for immunotherapy.

A hybrid herpes-assisted vector expansion process improves rAAV yield, potency, and purity from small seed quantities.

CRC sequences and DNA templates enable larger, more stable circularized RNA for improved translation and therapeutic expression.

Deleting CD7 and TRAC creates fratricide-resistant, potentially off-the-shelf CAR-T cells without GvHD.

MiniCircle DNA overcomes plasmid backbone silencing to achieve stable, long-term bispecific antibody production.

Modified AAV capsids release into culture media for direct supernatant harvesting, avoiding intracellular debris from cell disruption.

Aligning singletons with functional consensus sequences resolves low packaging yield and transduction efficiency in AAV vectors.

Codon optimized Factor IX nucleotide sequences boost protein productivity, resolving the trade-off between high expression and treatment cost.

Chimpanzee-derived adenovirus vectors elicit potent immune responses, overcoming pre-existing human immunity that limits traditional serotype vaccines.

Modified single-strand mRNA reprograms somatic cells without genome integration, eliminating cancer risk from viral delivery while maintaining high efficiency.

Modifying immune effector cells to enhance proliferation and cytotoxicity.

Organizing nucleic acid sequences encoding 4-1BBL, scIL-12, and IL-2 in a specific vector structure overcomes cancer cell immune evasion strategies.

Adeno-associated virus vectors deliver anti-IgE genes to overcome short protection durations from frequent monoclonal antibody injections.

Centrifugation chamber concentrates stem cells and viral vectors to resolve low transduction efficiency in automated genetic modification.

A protein complex with mitochondrial localization sequences targets nucleic acids for precise editing.

Engineered Ad35 vectors reduce immunogenicity while enabling targeted gene delivery to hematopoietic stem cells through CD46 binding.

Segmented adenoviral vectors enable reliable multi-gene insertion, reducing costs and improving physiological outcomes.

Avian adeno-associated virus vectors bypass human pre-existing antibodies to enable efficient gene transfer in resistant cells.

Fed-batch fermentation with temperature shifts boosts plasmid DNA yield while maintaining purity.

Stabilized formulations maintain viral integrity at elevated temperatures, eliminating the need for ultra-low cold chain infrastructure.

Diatomaceous earth pre-filters remove cells to prevent 0.45 μm membrane clogging by host proteins and DNA.

Droplet digital PCR detects seven replication-competent adenoviruses in 3x10^10 particles, resolving low-sensitivity limits of traditional roller bottle assays.

Ethyl alcohol and polyamines boost transfection efficiency in mature platelets, resolving low efficacy limits in gene therapy.

Self-cleaving ribozymes and annealing regions enable efficient circularization of linear polyribonucleotides, enhancing stability against degradation.

A scalable serum-free suspension cell culture system produces high-titer recombinant lentiviral vectors.

Targeted amino acid substitutions in the capsid protein reduce immunogenicity while increasing transduction efficiency for liver cancer gene therapy.

AAV vectors deliver CRISPR-Cas components to liver cells, resolving toxicity and off-target effects during in vivo genome editing.

Targeted amino acid substitutions in AAV2 capsid proteins increase liver transduction efficiency up to 250-fold compared to wild-type particles.

Combining ELISA with CryoTEM measures AAV concentration and potency, reducing variability found in qPCR methods.

Beta-cell-mimetic cells self-regulate insulin secretion via carbohydrate-inducible transcriptional systems.